News
Nonacus ranked third fastest growing technology company in the UK in the Deloitte Technology Fast 50
November 24, 2022 | COMPANY | NEWS Nonacus has been ranked within the top three fastest growing tech companies in the U.K, and first in healthcare, at the prestigious 2022 Deloitte Tech Fast 50 awards. The Deloitte UK Technology Fast 50 is a ranking of the 50 fastest-growing technology companies in the UK. The rankings…
Read MoreCell3™ Target becomes the first pan-cancer NGS panel for liquid biopsy profiling of childhood cancer
July 7, 2022 | ONCOLOGY | COMPANY | NEWS “We’ve created the first pan-cancer DNA sequencing panel that we know to be optimised for cell free DNA (cfDNA) in paediatric solid tumours” – Reda Stankunaite, Institute of Cancer Research Paediatric cancers are the leading cause of disease-related deaths among children who survive past infancy in…
Read MoreMay 17, 2022 | COMPANY | NEWS The latest results: 2022 update Last July we announced that Nonacus and the University of Birmingham had partnered to develop a non-invasive test for bladder cancer. The test uses highly sensitive liquid biopsy technology developed by Nonacus, and a panel of biomarkers validated by Dr Rik Bryan and…
Read MoreCell3 Target technology assists with targeted DNA methylation sequencing
November 11, 2021 | COMPANY | NEWS Researchers at The Centre For Genomic and Experimental Medicine, University of Edinburgh, have used Nonacus Cell3 Target technology to undertake targeted DNA methylation sequencing with the aim of finding DNA methylation specific breast cancer markers. This work is funded by Cancer Research UK. Nonacus spoke to Dr. Martyna Adamowicz from the…
Read MoreMarch 8, 2021 | COVID-19 | SERVICE We are now offering a Whole Genome Sequencing service to support SARS-CoV-2 testing laboratories, enabling them to provide Day 2 testing for ‘Test to Release’ in the UK. Government regulations, recently announced, set out the minimum standards that private sector providers must meet for SARS-CoV-2 tests for people arriving…
Read MoreDecember 18, 2020 | COMPANY Nonacus. The name behind non-invasive genomic diagnostics When Chris and Lee founded Nonacus in 2015 they had one singular purpose – to develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn’t easy. Based off the Latin term…
Read MoreDelivering the potential of cancer genomics to patients
June 15th, 2020 | COMPANY | ONCOLOGY Dante Labs, Cambridge Cancer Genomics and Nonacus collaborate to provide precision oncology at scale CAMBRIDGE (UK), L’AQUILA (Italy) and BIRMINGHAM (UK), 15 June 2020: Dante Labs, a pioneer and leader in genomic testing, Cambridge Cancer Genomics (CCG.ai), a software developer specialising in data-driven precision oncology, and Nonacus, a…
Read MoreSeptember 17, 2017 | COMPANY | NEWS Nonacus announced today the launch of a new DNA extraction kit designed to assist both researchers and clinicians translate the huge potential of circulating cell-free DNA into improved patient care. Non-invasive screening of cell-free DNA has already revolutionised the screening of conditions such as Down Syndrome in…
Read More- « Previous
- 1
- 2